STOCK TITAN

LianBio Announces Departure of Chief Financial Officer

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
LianBio (Nasdaq: LIAN) announces resignation of CFO and appointment of Interim CFO
Positive
  • None.
Negative
  • None.

SHANGHAI, China and PRINCETON, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yi Larson, Chief Financial Officer, has resigned from LianBio to pursue other opportunities, effective December 19, 2023.

In connection with her departure, the LianBio Board of Directors has appointed Ehong (Maggie) Gu, current VP, Head of Global Finance, as Interim Chief Financial Officer.

“We are grateful to Yi for her many contributions to strategic initiatives at LianBio and wish her continued success in her next role,” said Konstantin Poukalov, Executive Chairman of the LianBio Board of Directors.

About LianBio
LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For additional information, please visit the company’s website at www.lianbio.com.

For investor inquiries, please contact:
Elizabeth Anderson, VP Communications and Investor Relations
E: elizabeth.anderson@lianbio.com
T: (646) 655-8390

For media inquiries, please contact:
Katherine Smith, Evoke Canale
E: katherine.smith@evokegroup.com
T: (619) 849-5378


Yi Larson, Chief Financial Officer, has resigned from LianBio and Ehong (Maggie) Gu, current VP, Head of Global Finance, has been appointed as Interim Chief Financial Officer.

The resignation of the CFO took effect on December 19, 2023.

The ticker symbol for LianBio is LIAN.

LianBio is dedicated to bringing innovative medicines to patients in China and other major Asian markets.

Konstantin Poukalov is the Executive Chairman of the LianBio Board of Directors.
LianBio

NASDAQ:LIAN

LIAN Rankings

LIAN Latest News

LIAN Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services

About LIAN

lianbio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in china and major asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. lianbio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.